Search results
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga· 18 hours agoMonday, Moderna Inc MRNA and Merck & Co Inc MRK announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The ...
Merck to Acquire EyeBio
Morningstar· 6 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today ...
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Simply Wall St. via Yahoo Finance· 3 days agoWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 22 hours ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion By Reuters
Investing.com· 6 days agoIt agreed to pay $1.3 billion in cash and another $1.7 billion in future milestone-based payments...
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
Zacks via Yahoo Finance· 6 days agoMerck KGaA (MKGAF) made it through our "Recent Price Strength" screen and could be a great choice...
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
Reuters via Yahoo Finance· 6 days ago(Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion,...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Reuters via AOL· 6 days agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to...
Merck is spending $3 billion on an eye drug developer as it braces to lose a key cancer patent
Quartz· 6 days agoPharma giant Merck said on Wednesday that it is acquiring the privately-held eye drug developer...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 15 hours agoInsights from TIME, The Washington Post, MIT Technology Review The News Pharmaceutical giants...
